Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Rheumatoid Arthritis · Warm Antibody Autoimmune Hemolytic Anemia · RIGL

RIGEL PHARMACEUTICALS

RIGEL PHARMACEUTICALS INC

RIGEL PHARMACEUTICALS clinical programs — 36 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
1180 Veterans Blvd, South San Francisco, CA 94080, US HQ
1996 Founded
286 Employees
Public company Type
RIGL · NYSE Ticker
Company details
Status
Public
HQ
1180 Veterans Blvd, South San Francisco, CA 94080, US
Founded
1996
Employees
286
Programs
36
Drugs
26
Patents
373
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

RIGEL PHARMACEUTICALS projects

36 ClinicalTrials.gov programs sponsored by RIGEL PHARMACEUTICALS.

RIGEL PHARMACEUTICALS has 36 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

36 programs

Clinical programs

  1. Fostamatinib

    RIGEL PHARMACEUTICALS INC

    Covid19

    phase 3 small molecule completed

    1 trial

  2. Fostamatinib disodium

    RIGEL PHARMACEUTICALS INC

    Warm Antibody Autoimmune Hemolytic Anemia

    phase 3 small molecule active

    2 trials

  3. Fostamatinib disodium

    RIGEL PHARMACEUTICALS INC

    Immune Thrombocytopenic Purpura

    phase 3 small molecule completed

    3 trials

  4. Fostamatinib

    RIGEL PHARMACEUTICALS INC

    Hidradenitis Suppurativa

    phase 2 small molecule completed

    1 trial

  5. Fostamatinib

    RIGEL PHARMACEUTICALS INC

    Myelofibrosis

    phase 2 small molecule terminated

    1 trial

  6. Fostamatinib 150 mg

    RIGEL PHARMACEUTICALS INC

    IGA Nephropathy

    phase 2 small molecule completed

    1 trial

  7. Fostamatinib 150 mg bid

    RIGEL PHARMACEUTICALS INC

    Warm Antibody Autoimmune Hemolytic Anemia

    phase 2 small molecule completed

    1 trial

  8. Fostamatinib Disodium

    RIGEL PHARMACEUTICALS INC

    T Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  9. Fostamatinib Disodium (R935788)

    RIGEL PHARMACEUTICALS INC

    Systemic Lupus Erythematosus

    phase 2 small molecule terminated

    1 trial

  10. Fostamatinib Disodium / R935788

    RIGEL PHARMACEUTICALS INC

    Purpura, Thrombocytopenic, Idiopathic

    phase 2 small molecule completed

    1 trial

  11. Fostamatinib Disodium tablet 100 mg

    RIGEL PHARMACEUTICALS INC

    IGA Nephropathy

    phase 2 small molecule terminated

    1 trial

  12. Fostamatinib disodium (R935788)

    RIGEL PHARMACEUTICALS INC

    Rheumatoid Arthritis

    phase 2 small molecule completed

    2 trials

  13. LY3871801

    RIGEL PHARMACEUTICALS INC

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  14. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  15. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  16. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Targeted Therapy

    phase 2 small molecule active

    1 trial

  17. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Chronic Myelomonocytic Leukemia

    phase 2 small molecule terminated

    1 trial

  18. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Mutant IDH1 Inhibitor Olutasidenib

    phase 2 small molecule active

    1 trial

  19. Olutasidenib + TMZ

    RIGEL PHARMACEUTICALS INC

    High Grade Glioma

    phase 2 small molecule active

    1 trial

  20. Placebo

    RIGEL PHARMACEUTICALS INC

    Asthma

    phase 2 small molecule completed

    1 trial

  21. Placebo

    RIGEL PHARMACEUTICALS INC

    Acute Respiratory Distress Syndrome

    phase 2 small molecule active

    1 trial

  22. R348 Ophthalmic Solution, 0.2%

    RIGEL PHARMACEUTICALS INC

    Keratoconjunctivitis Sicca

    phase 2 small molecule completed

    2 trials

  23. R348 Ophthalmic Solution, 0.2%

    RIGEL PHARMACEUTICALS INC

    Chronic Graft-versus-host Disease

    phase 2 small molecule completed

    1 trial

  24. R788

    RIGEL PHARMACEUTICALS INC

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  25. R906289 Monosodium (R289 Na)

    RIGEL PHARMACEUTICALS INC

    Low Risk Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  26. R926112

    RIGEL PHARMACEUTICALS INC

    Rhinitis, Allergic, Seasonal

    phase 2 small molecule completed

    1 trial

  27. R932333

    RIGEL PHARMACEUTICALS INC

    Lupus Erythematosus, Discoid

    phase 2 small molecule completed

    1 trial

  28. Ruxolitinib

    RIGEL PHARMACEUTICALS INC

    Coronavirus

    phase 2 small molecule completed

    1 trial

  29. fostamatinib

    RIGEL PHARMACEUTICALS INC

    Lymphoma

    phase 2 small molecule completed

    1 trial

  30. Fostamatinib

    RIGEL PHARMACEUTICALS INC

    Chronic Graft Versus Host Disease

    phase 1 small molecule active

    1 trial

  31. Fostamatinib 100 mg bid and Paclitaxel

    RIGEL PHARMACEUTICALS INC

    Ovarian Cancer

    phase 1 small molecule completed

    1 trial

  32. Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)

    RIGEL PHARMACEUTICALS INC

    Pancreatic Ductal Adenocarcinoma (PDAC)

    phase 1 other active

    1 trial

  33. Olutasidenib Investigational Agent Administration

    RIGEL PHARMACEUTICALS INC

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  34. GAVRETO ®(pralsetinib) capsules

    RIGEL PHARMACEUTICALS INC

    Patients with advanced or metastatic solid tumors

    approved small molecule active

    1 trial

  35. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    AML (Acute Myeloid Leukemia)

    approved small molecule active

    1 trial

  36. imiquimod 5% cream

    RIGEL PHARMACEUTICALS INC

    Actinic Keratoses

    approved small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does RIGEL PHARMACEUTICALS have?

36 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.